Compared with standard care, carbidogopa levodopa enteral suspension is more cost-effective.

Published Date: 16 Nov 2023

An incremental cost-effectiveness ratio of $7711/QALY was found in a real-world study comparing the cost-effectiveness of carbidoglopaprofenopa levodopa enteral suspension for Parkinson disease to standard care.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot